Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Journal articles
, 2024, '274 Oleogel-S10 reduces dressing changes burden and associated costs in patients with epidermolysis bullosa', Journal of Investigative Dermatology, 144, pp. S47 - S47, http://dx.doi.org/10.1016/j.jid.2024.06.290
, 2024, '53652 Efficacy and safety of eblasakimab in adults with severe atopic dermatitis: a posthoc analysis of the Phase 2b TREK-AD trial', Journal of the American Academy of Dermatology, 91, pp. ab194, http://dx.doi.org/10.1016/j.jaad.2024.07.773
, 2024, '53738 Patient-Reported Outcomes and Safety in Adolescent and Adult Atopic Dermatitis Patients Treated with Dupilumab: Real-World Insights One Year into the GLOBOSTAD Multinational Prospective Observational Study', Journal of the American Academy of Dermatology, 91, pp. ab276, http://dx.doi.org/10.1016/j.jaad.2024.07.1098
, 2024, '553 Development of Bacteria Activated Stimuli-Response Dressing for Management of Infection in Epidermolysis Bullosa', Journal of Investigative Dermatology, 144, pp. S324 - S324, http://dx.doi.org/10.1016/j.jid.2024.10.566
, 2024, 'Evaluation of Skin of Color Publication Trends over the Past Two Decades in the Journal of the American Academy of Dermatology (vol 89, pg 614, 2023)', JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 90, pp. 881 - 881, http://dx.doi.org/10.1016/j.jaad.2024.01.005
, 2023, 'Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: A 30-month experience', Clinical and Experimental Dermatology, 48, pp. 1266 - 1269, http://dx.doi.org/10.1093/ced/llad215
, 2023, 'Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1211 - e1214, http://dx.doi.org/10.1111/jdv.19195
, 2023, 'Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study', British Journal of Dermatology, 189, pp. 392 - 399, http://dx.doi.org/10.1093/bjd/ljad182
, 2023, 'The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid', Journal of Investigative Dermatology, 143, pp. 1868 - 1871, http://dx.doi.org/10.1016/j.jid.2023.03.1673
, 2023, 'Evaluation of skin of color publication trends over the past 2 decades in the Journal of the American Academy of Dermatology', Journal of the American Academy of Dermatology, 89, pp. 614 - 616, http://dx.doi.org/10.1016/j.jaad.2023.05.036
, 2023, 'Immunisation status during biologic therapy for hidradenitis suppurativa and psoriasis', JEADV Clinical Practice, 2, pp. 549 - 552, http://dx.doi.org/10.1002/jvc2.182
, 2023, 'Interventions for bullous pemphigoid', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD002292.pub4
, 2023, 'A Review of the Scoring and Assessment of Keratosis Pilaris', Skin Appendage Disorders, 9, pp. 241 - 251, http://dx.doi.org/10.1159/000529487
, 2023, 'Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study', Clinical and Experimental Dermatology, 48, pp. 765 - 769, http://dx.doi.org/10.1093/ced/llad105
, 2023, 'Dermatoethics: Nepotism in dermatology residencies', Journal of the American Academy of Dermatology, 89, pp. 193 - 194, http://dx.doi.org/10.1016/j.jaad.2022.01.011
, 2023, 'Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1366 - 1374, http://dx.doi.org/10.1111/jdv.18914
, 2023, 'The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial', Lancet Rheumatology, 5, pp. e413 - e421, http://dx.doi.org/10.1016/S2665-9913(23)00131-5
, 2023, 'BG04 Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study', British Journal of Dermatology, 188, pp. ljad113.144, http://dx.doi.org/10.1093/bjd/ljad113.144
, 2023, 'Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial', Journal of Drugs in Dermatology, 22, pp. 599 - 604, http://dx.doi.org/10.36849/JDD.7108
, 2023, 'Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis', Clinical and Experimental Dermatology, 48, pp. 623 - 630, http://dx.doi.org/10.1093/ced/llad033
, 2023, 'Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study', Dermatology and Therapy, 13, pp. 1255 - 1264, http://dx.doi.org/10.1007/s13555-023-00923-1
, 2023, 'Use of a hybrid teledermatology model in an Australian tertiary hospital during the COVID-19 pandemic', Jaad International, 11, pp. 33 - 34, http://dx.doi.org/10.1016/j.jdin.2022.03.016
, 2023, 'ISID0459 - Demographics, comorbidities and disease severity before dupilumab treatment initiation in Asian patients with atopic dermatitis', , http://dx.doi.org/10.26226/m.641999e770c3630019098d8e
, 2023, 'ISID0396 - A novel investigator global assessment score for the evaluation of keratosis pilaris', , http://dx.doi.org/10.26226/m.641999e460d56100127c27b2
, 2023, 'A review of JAK and IL-23 inhibitors to treat vitiligo', Australasian Journal of Dermatology, 64, pp. 204 - 212, http://dx.doi.org/10.1111/ajd.14001
, 2023, 'Evaluating the nature and prevalence of glucocorticoid-induced type 2 diabetes mellitus in patients with autoimmune bullous diseases', Clinical and Experimental Dermatology, 48, pp. 448 - 452, http://dx.doi.org/10.1093/ced/llac137
, 2023, 'ISID0390 - Examining the risk factors for worsened glucocorticoid morbidity in a prospective, multicentre, international study of patients with autoimmune blistering diseases.', , http://dx.doi.org/10.26226/m.641999e288811f001400fb3d
, 2023, 'Median canaliform nail dystrophy in a 2-year-old boy: Case report and review of the literature', Pediatric Dermatology, 40, pp. 511 - 518, http://dx.doi.org/10.1111/pde.15181
, 2023, 'Primary cutaneous amyloidosis: A review of the available studies and gaps in data', Australasian Journal of Dermatology, 64, pp. e121 - e124, http://dx.doi.org/10.1111/ajd.14012
, 2023, 'Fibrillar matrix, Echogenicity, Contour, Thickness, and Suture (FECTS) vs. Global: A comparison of 2 scales developed to assess ultrasound images post rotator cuff repair', Journal of Shoulder and Elbow Surgery, 32, pp. 713 - 728, http://dx.doi.org/10.1016/j.jse.2022.10.035
, 2023, 'Gender Equity in Medicine and Dermatology in the United States: The Long Road Traveled and the Journey ahead', Dermatologic Clinics, 41, pp. 265 - 278, http://dx.doi.org/10.1016/j.det.2022.08.007
, 2023, 'Pemphigus scoring systems and their validation studies – A review of the literature', Dermatologica Sinica, 41, pp. 67 - 77, http://dx.doi.org/10.4103/ds.DS-D-22-00150
, 2023, 'Clinical manifestations of alopecia in autoimmune blistering diseases: A cross-sectional study', Jaad International, 10, pp. 6 - 13, http://dx.doi.org/10.1016/j.jdin.2022.08.025
, 2023, 'The dangers of social media: patients with atopic dermatitis ceasing their basic treatment', Clinical and Experimental Dermatology, 48, pp. 142 - 143, http://dx.doi.org/10.1093/ced/llac056
, 2023, 'Tildrakizumab for the treatment of exfoliative cheilitis', Mucosa, 6, pp. 19 - 21, http://dx.doi.org/10.33204/mucosa.1209480
, 2023, '307 The study design of a trial of dupilumab in adult patients with bullous pemphigoid (BP): LIBERTY-BP ADEPT', British Journal of Dermatology, 188, pp. ljac140.007, http://dx.doi.org/10.1093/bjd/ljac140.007
, 2023, 'Podiatric assessment in children and adults with epidermolysis bullosa: are foot and ankle patientreported outcome measures (PROMs) able to measure the severity of podiatric involvement among EB patients?', International Journal of Women S Dermatology, 9, pp. E046, http://dx.doi.org/10.1097/JW9.0000000000000046
, 2023, 'Autoimmune blistering skin diseases triggered by COVID-19 vaccinations: An Australian case series', Frontiers in Medicine, 9, http://dx.doi.org/10.3389/fmed.2022.1117176
, 2023, 'A life for autoimmune blistering diseases: in memoriam Detlef Zillikens', Frontiers in Immunology, 14, http://dx.doi.org/10.3389/fimmu.2023.1291590
, 2023, 'Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia', Frontiers in Medicine, 10, http://dx.doi.org/10.3389/fmed.2023.1149742
, 2023, 'Editorial: Challenges of COVID-19 in dermatology patients on immunosuppression: risk, outcome, vaccination and beyond, volume II', Frontiers in Medicine, 10, http://dx.doi.org/10.3389/fmed.2023.1268285
, 2023, 'Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study', British Journal of Dermatology, 188, pp. 12 - 21, http://dx.doi.org/10.1093/bjd/ljac001
, 2023, 'From the Cochrane Library: Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus', Jmir Dermatology, 6, http://dx.doi.org/10.2196/46812
, 2023, 'Practice Dilemma: Expanding Melanonychia in the Paediatric Setting', Skin Appendage Disorders, 9, pp. 58 - 60, http://dx.doi.org/10.1159/000526102
, 2023, 'Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases', Frontiers in Immunology, 14, http://dx.doi.org/10.3389/fimmu.2023.1243581
, 2023, '390 Examining the risk factors for worsened glucocorticoid morbidity in a prospective, multicentre, international study of patients with autoimmune blistering diseases', Journal of Investigative Dermatology, 143, pp. S67 - S67, http://dx.doi.org/10.1016/j.jid.2023.03.396
, 2023, '396 A novel investigator global assessment score for the evaluation of keratosis pilaris', Journal of Investigative Dermatology, 143, pp. S68 - S68, http://dx.doi.org/10.1016/j.jid.2023.03.402
, 2023, '459 Demographics, comorbidities and disease severity before dupilumab treatment initiation in Asian patients with atopic dermatitis', Journal of Investigative Dermatology, 143, pp. S79 - S79, http://dx.doi.org/10.1016/j.jid.2023.03.465
, 2023, '639 Design of marigold-bp: A phase 2/3 study of nipocalimab in adults with moderate to severe bullous pemphigoid', Journal of Investigative Dermatology, 143, pp. s109, http://dx.doi.org/10.1016/j.jid.2023.03.646
, 2023, 'Detlef Zillikens, 1958-2022', Journal of Investigative Dermatology, 143, pp. 7 - 8, http://dx.doi.org/10.1016/j.jid.2022.11.001